Vandetanib clinical trials
Vandetanib is named as an intervention in 3 current clinical trials in our China, France, UK, USA, India, Germany, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Canada, Brazil, Japan, South Korea, Australia and Israel registers. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Loxo Oncology, Inc (1). The most-studied condition is Medullary Thyroid Cancer.
Where Vandetanib is approved
All regulators →Of the three regulators tracked here, the first to approve Vandetanib was the US, on 6 Apr 2011. It is approved in 3 of the 3 regulators tracked here.
- 1 EU orphan designation, most recently for treatment of medullary thyroid carcinoma (24 Jan 2006, withdrawn)
- 1 EU safety letter (DHPC), latest: restriction of indication for Caprelsa, 28 Feb 2023
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Vandetanib patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Vandetanib, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 1 listed patent; the last listed expires 8 Aug 2028 (US 8067427).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
How Vandetanib works
All drug targets →- Tyrosine-protein kinase SRC inhibitor InhibitorTarget: SRC SRC proto-oncogene, non-receptor tyrosine kinaseChEMBL only
- Tyrosine-protein kinase BRK inhibitor InhibitorTarget: PTK6 protein tyrosine kinase 6ChEMBL only
- Tyrosine-protein kinase TIE-2 inhibitor InhibitorTarget: TEK TEK receptor tyrosine kinaseChEMBL only
- Vascular endothelial growth factor receptor inhibitor InhibitorTarget: Vascular endothelial growth factor receptor✓ In ChEMBL and the Guide to Pharmacology
- Tyrosine-protein kinase receptor RET inhibitor InhibitorTarget: RET ret proto-oncogene✓ In ChEMBL and the Guide to Pharmacology
- Ephrin receptor inhibitor InhibitorTarget: Ephrin receptorChEMBL only
- Epidermal growth factor receptor inhibitor InhibitorTarget: Epidermal growth factor receptor✓ In ChEMBL and the Guide to Pharmacology
- Non-small cell lung carcinomaPhase 3
- Thyroid cancerPhase 3
- Acute myeloid leukemiaPhase 2
- Bile duct carcinomaPhase 2
- Breast cancerPhase 2
- CarcinomaPhase 2
- Clear cell renal carcinomaPhase 2
- Colorectal cancerPhase 2
- Exocrine pancreatic carcinomaPhase 2
- Fallopian tube cancerPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL24828, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 5717, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Vandetanib
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Vandetanib. 1 is current.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Vandetanib for treating medullary thyroid cancer NICE TA550 | Not recommended | 12 Dec 2018 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Vandetanib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 2 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: CaprelsaEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Vandetanib
- ATC code
- L01XE12
- ChEMBL
- CHEMBL24828
- DrugBank
- DB05294
- PubChem CID
- 3081361
- CAS number
- 443913-73-3
- FDA UNII
- YO460OQ37K
- Wikidata
- Q7914515
- Wikipedia
- Vandetanib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Vandetanib
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
NCT06482086 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma
|
Phase 2 | Recruiting | West China Hospital | China |
|
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337 · Medullary Thyroid Cancer
|
Phase 3 | Active, closed | Loxo Oncology, Inc | UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Canada, Brazil, Japan, South Korea, Australia, Israel |
|
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
NCT02299999 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer
|
Phase 2 | Active, closed | UNICANCER | France |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Vandetanib across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
2 single-substance products containing Vandetanib on the HPRA medicines list.
- Caprelsa 100 mg film-coated tabletsEsteve Pharmaceuticals S.A. · EU/1/11/749/001
- Caprelsa 300 mg film-coated tabletsEsteve Pharmaceuticals S.A. · EU/1/11/749/002
Supply shortages
No entry for Vandetanib in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Vandetanib
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Loxo Oncology, Inc | 1 |
| West China Hospital | 1 |
| UNICANCER | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Vandetanib trials
How many clinical trials are testing Vandetanib?
3 current trials in our China, France, UK, USA, India, Germany, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Canada, Brazil, Japan, South Korea, Australia and Israel registers name Vandetanib as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Vandetanib trials recruiting patients?
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Vandetanib clinical trials?
Loxo Oncology, Inc (1), West China Hospital (1) and UNICANCER (1). The number in brackets is how many trials each organisation leads.
Is Vandetanib licensed in Ireland?
Yes. The HPRA medicines list includes 2 single-substance products containing Vandetanib, for example Caprelsa 100 mg film-coated tablets (Esteve Pharmaceuticals S.A.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Vandetanib shortage?
Not in the lists we track: Vandetanib has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Vandetanib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Vandetanib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Vandetanib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.